An open phase I study to assess the biological effects of a continuous intravenous infusion of Interleukin-3 followed by Granulocyte Macrophage-Colony Stimulating Factor.

2.50
Hdl Handle:
http://hdl.handle.net/10541/95598
Title:
An open phase I study to assess the biological effects of a continuous intravenous infusion of Interleukin-3 followed by Granulocyte Macrophage-Colony Stimulating Factor.
Authors:
Bretti, S; Gilleece, M H; Kamthan, A; Fitzsimmons, L; Hicks, F; Rowlands, M; Bishop, P; Picardo, A M; Dexter, T Michael; Scarffe, J Howard
Abstract:
To assess any synergistic stimulatory effect in vivo of Interleukin 3 (IL-3) and Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) upon white cell and platelet counts, toxicity and antitumour effect, we conducted this phase I study. IL-3 0.25, 0.5 or 5 micrograms/kg/day for 1, 4 or 7 days was given by continuous intravenous (i.v.) infusion to 35 patients with advanced malignancy. 21 of the 35 patients also received sequential or overlapping treatment with continuous i.v. infusion of GM-CSF 1 or 3 micrograms/kg/day for up to 10 days. Monotherapy with IL-3 producted significant dose related increases in platelets and white cell counts. Combinations of IL-3 and GM-CSF also produced increases in white cell counts, but these were no greater than would be expected following GM-CSF treatment alone. There was a trend for platelets to increase more in patients receiving IL-3 and GM-CSF than those receiving IL-3 alone, but this did not reach statistical significance. In general, IL-3 and combinations of IL-3 and GM-CSF were well tolerated and the most common side-effect was fever. A maximum tolerated dose was not reached and antitumour effects were not seen. Future studies using combinations of IL-3 5 micrograms/kg/day and GM-CSF 3 micrograms/kg/day may help to define the optimal therapeutic regimen.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital Trust, Manchester, UK.
Citation:
An open phase I study to assess the biological effects of a continuous intravenous infusion of Interleukin-3 followed by Granulocyte Macrophage-Colony Stimulating Factor. 1996, 32A (7):1171-8 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
Jun-1996
URI:
http://hdl.handle.net/10541/95598
DOI:
10.1016/0959-8049(96)00027-5
PubMed ID:
8758249
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorBretti, Sen
dc.contributor.authorGilleece, M Hen
dc.contributor.authorKamthan, Aen
dc.contributor.authorFitzsimmons, Len
dc.contributor.authorHicks, Fen
dc.contributor.authorRowlands, Men
dc.contributor.authorBishop, Pen
dc.contributor.authorPicardo, A Men
dc.contributor.authorDexter, T Michaelen
dc.contributor.authorScarffe, J Howarden
dc.date.accessioned2010-04-06T09:00:16Z-
dc.date.available2010-04-06T09:00:16Z-
dc.date.issued1996-06-
dc.identifier.citationAn open phase I study to assess the biological effects of a continuous intravenous infusion of Interleukin-3 followed by Granulocyte Macrophage-Colony Stimulating Factor. 1996, 32A (7):1171-8 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid8758249-
dc.identifier.doi10.1016/0959-8049(96)00027-5-
dc.identifier.urihttp://hdl.handle.net/10541/95598-
dc.description.abstractTo assess any synergistic stimulatory effect in vivo of Interleukin 3 (IL-3) and Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) upon white cell and platelet counts, toxicity and antitumour effect, we conducted this phase I study. IL-3 0.25, 0.5 or 5 micrograms/kg/day for 1, 4 or 7 days was given by continuous intravenous (i.v.) infusion to 35 patients with advanced malignancy. 21 of the 35 patients also received sequential or overlapping treatment with continuous i.v. infusion of GM-CSF 1 or 3 micrograms/kg/day for up to 10 days. Monotherapy with IL-3 producted significant dose related increases in platelets and white cell counts. Combinations of IL-3 and GM-CSF also produced increases in white cell counts, but these were no greater than would be expected following GM-CSF treatment alone. There was a trend for platelets to increase more in patients receiving IL-3 and GM-CSF than those receiving IL-3 alone, but this did not reach statistical significance. In general, IL-3 and combinations of IL-3 and GM-CSF were well tolerated and the most common side-effect was fever. A maximum tolerated dose was not reached and antitumour effects were not seen. Future studies using combinations of IL-3 5 micrograms/kg/day and GM-CSF 3 micrograms/kg/day may help to define the optimal therapeutic regimen.en
dc.language.isoenen
dc.subjectHaemoglobinsen
dc.subjectCanceren
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshBone Marrow-
dc.subject.meshBone Marrow Examination-
dc.subject.meshDose-Response Relationship, Drug-
dc.subject.meshDrug Synergism-
dc.subject.meshDrug Therapy, Combination-
dc.subject.meshFemale-
dc.subject.meshGranulocyte-Macrophage Colony-Stimulating Factor-
dc.subject.meshHemoglobins-
dc.subject.meshHumans-
dc.subject.meshInfusions, Intravenous-
dc.subject.meshInterleukin-3-
dc.subject.meshLeukocyte Count-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasms-
dc.subject.meshPlatelet Count-
dc.subject.meshRecombinant Proteins-
dc.titleAn open phase I study to assess the biological effects of a continuous intravenous infusion of Interleukin-3 followed by Granulocyte Macrophage-Colony Stimulating Factor.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital Trust, Manchester, UK.en
dc.identifier.journalEuropean Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.